Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial
Details
Publication Year 2025-05-20,Volume 43,Issue #15,Page 1758-1764
Journal Title
Journal of Clinical Oncology
Publication Type
Research article
Abstract
LIBRETTO-001 (ClinicalTrials.gov identifier: NCT03157128) is a registrational phase I/II, single-arm, open-label trial of selpercatinib in RET-dependent cancers. With 19 months of additional follow-up, we report the final efficacy and safety results of selpercatinib in patients with RET fusion-positive non-small cell lung cancer (NSCLC) who had previously received platinum-based chemotherapy (N = 247) or were treatment-naïve (N = 69). The objective response rate (ORR) was 62% for pretreated patients and 83% for treatment-naïve patients. Duration of response (DoR) was 31.6 months for pretreated and 20.3 months for treatment-naïve patients (median follow-up approximately 38 months). Median progression-free survival (PFS) was 26.2 months for pretreated and 22.0 months for treatment-naïve patients (median follow-up approximately 40 months). Median overall survival was 47.6 months in pretreated patients and was not reached in the treatment-naïve group (median follow-up approximately 43 months). At the 3-year landmark estimate, 57% of pretreated and 66% of treatment-naïve patients were alive. Among 26 patients with measurable CNS metastases at baseline, the CNS-ORR was 85% with a CNS-DoR of 9.4 months and CNS-PFS of 11.0 months. The safety profile of selpercatinib was consistent with previous reports. With substantial additional follow-up, selpercatinib continued to show durable responses and intracranial activity, with a manageable safety profile in patients with RET fusion-positive NSCLC.
Publisher
American Society of Clinical Oncology
Keywords
Humans; *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/mortality/pathology; *Lung Neoplasms/drug therapy/genetics/pathology/mortality; Male; Female; Middle Aged; *Proto-Oncogene Proteins c-ret/genetics; Aged; Adult; *Pyrazoles/therapeutic use/adverse effects; *Pyridines/therapeutic use/adverse effects; *Oncogene Proteins, Fusion/genetics; *Protein Kinase Inhibitors/therapeutic use/adverse effects; Progression-Free Survival; Aged, 80 and over
Department(s)
Medical Oncology
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2025-03-18 06:23:42
Last Modified: 2025-06-02 01:58:43

© 2025 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙